Etienne G.C. Brain

Etienne G.C. Brain

Auto-generated profile, based on publicly available information

Etienne G.C. Brain

Institut Curie, Hôpital René Huguenin, Saint-Cloud, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2010 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CBChrystelle Brignone
Chrystelle Brignone
MGMaya Gutierrez
Maya Gutierrez
FMFawzia Mefti
Fawzia Mefti
EBEtienne Brain
Etienne Brain
RJRosana Jarcau
Rosana Jarcau
FTFrédéric Triebel
Frédéric Triebel
Background: IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC) receiving first-line paclitaxel weekly, 3 weeks out of 4. Methods: MBC patients were administered one dose of IMP321 s.c. every two weeks for a total of 24 weeks (12 injections). The repeated single doses were administered the day after chemotherapy at D2 and D16 of the 28-day cycles of paclitaxel (80 mg/m2 at D1, D8 and D15, for 6 cycles). Blood samples were taken 13 days after the sixth and the twelfth IMP321 injections to determine sustained APC, NK and memory CD8 T cell responses. Results: Thirty MBC patients received IMP321 in three cohorts (doses: 0.25, 1.25 and 6.25 mg). IMP321 induced both a sustained increase in the number and activation of APC (monocytes and dendritic cells) and an increase in the percentage of NK and long-lived cytotoxic effector-memory CD8 T cells. Clinical benefit was observed for 90% of patients with only 3 progressors at 6 months. Also, the objective tumor response rate of 50% compared favorably to the 25% rate reported in the historical control group. Conclusions: The absence of toxicity and the demonstration of activity strongly support the future development of this agent for clinical use in combined first-line regimens. Trial registration: ClinicalTrials.gov NCT00349934

18 October 2010 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MAM. Aapro
M. Aapro
CBC. Bernard-Marty
C. Bernard-Marty
EBE. G. C. Brain
E. G. C. Brain
GBG. Batist
G. Batist
FEF. Erdkamp
F. Erdkamp
UWU. Wedding
U. Wedding
Background: Comorbidities and risk factors likely to complicate treatment are common in elderly cancer patients. Anthracyclines remain the cornerstone of first-line therapy for non-Hodgkin’s lymphoma (NHL) and metastatic and early breast cancer but can cause congestive heart failure. Elderly patients are at increased risk of this event and measures to reduce it should be considered. Methods: A committee of experts in breast cancer and NHL met under the auspices of the International Society for Geriatric Oncology to review the literature and make recommendations, based on level of evidence, for the assessment, treatment and monitoring of elderly patients requiring anthracyclines. Results and recommendations: Use of anthracycline-based chemotherapy illustrates many of the dilemmas facing elderly cancer patients. Age in itself should not prevent access to potentially curative treatment or treatment that prolongs life or improves its quality. The risk of cardiotoxicity with conventional anthracyclines is increased by the following factors: an existing or history of heart failure or cardiac dysfunction; hypertension, diabetes and coronary artery disease; older age (independent of comorbidities and performance status); prior treatment with anthracyclines; higher cumulative dose of anthracyclines and short infusion duration. The fact that cumulative and irreversible cardiotoxicity is likely to be greater in this population than among younger patients calls for effective pretreatment screening for risk factors, rigorous monitoring of cardiac function and early intervention. Use of liposomal anthracycline formulations, prolonging the infusion time for conventional anthracyclines and cardioprotective measures should be considered. However, when treatment is being given with curative intent, care should be taken to ensure reduced cardiotoxicity is not achieved at the expense of efficacy.

1 October 2011 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
EBEtienne G.C. Brain
Etienne G.C. Brain
CMCécile Mertens
Cécile Mertens
VGVéronique Girre
Véronique Girre
FRFrédérique Rousseau
Frédérique Rousseau
EBEmmanuel Blot
Emmanuel Blot
MDMarc Debled
Marc Debled

1 June 2009 in Oncologie
Verified
Journal Article
Closed access
PDF file
HBH. Boyle
H. Boyle
VGV. Girre
V. Girre
CMC. Mertens
C. Mertens
CFC. Falandry
C. Falandry
FGF. Gouttenoire
F. Gouttenoire
EBE. G. C. Brain
E. G. C. Brain
Clinical research in geriatric oncology is still in its very early stages. However, the heterogeneous nature of the aging process requires specific programs addressing both old and new therapies for elderly cancer patients. The “Programme d’action concertée d’oncogériatrie” (GERICO group), launched in 2002 by the French National Federation of Cancer Centres (FNCLCC), has acquired and demonstrated this specific experience. Other initiatives include those of cooperative groups such as the European Organization for Research and Treatment of Cancer (EORTC) or the ARCAGY-GINECO group. New assessment criteria, focused on independence and quality of life, two key issues for the elderly, must be associated with the traditional axes of response and survival, whilst translational research is a key direction for future studies. La recherche clinique en oncogériatrie est encore balbutiante. Pourtant, l’hétérogénéité du vieillissement justifie le développement de programmes spécifiques aux sujets âgés s’adressant aux thérapeutiques classiques et innovantes. Le programme d’action concertée d’oncogériatrie (PAC GERICO) de la Fédération nationale des centres de lutte contre le cancer (FNCLCC) lancé, en 2002, en est un exemple. D’autres initiatives existent dans plusieurs groupes coopérateurs comme à l’European Organization for Research and Treatment of Cancer (EORTC) ou dans le groupe ARCAGY-GINECO. Cette recherche conduit à réfléchir à de nouveaux critères d’évaluation plus orientés sur l’autonomie et la qualitédevie, deux volets essentiels pour la population âgée, en association aux critères carcinologiques traditionnels de réponse et de survie. La recherche de transfert est un axe essentiel de développement.